Rayno Life Science Small Cap Picks: CLDX, PACB, FMI…Update-1

Update November 18 : NASDAQ 4702 up 0.67%, IBB at 295.25up 2.22% Recent Small Cap picks: CLDX 17.72 off 2.9% with profit taking.Very choppy trade. FCSC 2.67 flat little action, despite Press Release on amputee treatment. Foundation Medicine (FMI) at $25.86 up 2.67%. DNA tests for genetic profiling of potential cancer treatments. KPTI $40.71 flat […]

Continue Reading 0

Rayno Life Science: Biotech Stocks Hit A Wall At New Highs Up 40% YTD

 Red Tape Today Means Caution-Take Some Off XBI at $167.83 Off 2% Traders, investors, executives even pension funds are thrilled with biotech investing as the stock group rolls on to new highs this month. What may not be appreciated is the 20% move off the October 16 bottom when gloom and doom reached its nadir […]

Continue Reading 0

Rayno Life Science Stocks: Up 30%+ YTD After A Volatile October

Investors Whipsawed By V-Shaped Rally NASDAQ at New Highs 4631 DOW at New Highs 17,390 Investors got what was forecasted-a volatile October that moved from fear to greed in two weeks! The market was buffeted by the Ebola scare, macro analysts decrying easy money from the FED and a potential global economic slowdown. But fears […]

Continue Reading

Sierra SnowBlog Oct. 2014: White Is the New Orange

Update 11/5/14 No storms on the horizon for next week in the West, but check out this model for a “polar express” in the East and Midwest also creating a “blocking pattern” for the West: http://wxbrad.com/massive-storm-in-the-pacific-drives-arctic-outbreak-into-the-u-s-next-week/ Massive Storm in the Pacific drives Arctic Outbreak into the U.S Next Week. http://wp.me/p1srzO-1RZ Massive Storm in the Pacific […]

Continue Reading

Bio Investor Forum #2: T-Cell Therapies and Cancer Targets

Genetically Modified T-cells: Gene Therapy Is Back! Here are some quick notes and an overview of the companies at Bio: Immuno-Oncology  is one of the hottest new areas of biopharmaceutical development and on October 7  BIO presented a Therapeutic Session on “T-Cell Therapies: Best Bets in Pushing Down the Cost Curve and Prioritizing Cancer Targets”. […]

Continue Reading